Skip to main navigation Skip to search Skip to main content

A budget impact model for biosimilar infliximab in Crohns disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia

  • V. Brodszky
  • , F. Rencz
  • , M. Péntek
  • , P. Baji
  • , P.L. Lakatos
  • , L. Gulácsi

    Research output: Contribution to journal › Article (Academic Journal) › peer-review

    64 Citations (Scopus)
    Original languageEnglish
    JournalExpert Review of Pharmacoeconomics and Outcomes Research
    Early online date10 Jul 2015
    DOIs
    Publication statusPublished - 2016

    Cite this